Mr. Pierre Laurin reports

PROMETIC ENTERS INTO BINDING AGREEMENT TO SECURE $25 MILLION FOLLOW-ON FINANCING FROM STRUCTURED ALPHA LP, AN AFFILIATE OF THOMVEST ASSET MANAGEMENT INC.

ProMetic Life Sciences Inc. has entered into a binding agreement to secure a follow-on investment from Structured Alpha LP, an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc., consisting of a $25-million loan. As partial consideration for the loan, ProMetic will grant Structured Alpha LP 10,600,407 warrants with an exercise price of $3.70 per common share, a premium of 70 per cent to yesterday's closing share price, the whole subject to obtaining Toronto Stock Exchange approval and closing the definitive documentation, which the parties expect to achieve over the next 30 days.

"ProMetic is now only a few months away from officially becoming a fully integrated biopharmaceutical company with its first commercially approved drug, plasminogen, expected to be launched in Q4 this year," stated Pierre Laurin, president and chief executive officer of ProMetic Life Sciences. "It is key for us to remain sufficiently capitalized to execute on our corporate initiatives and clinical programs as we continue delivering on the expected catalysts events. We intend to fully leverage this follow-on investment to generate value for all our shareholders."

Commenting on the additional follow-on investment in ProMetic, Stefan Clulow, managing director and chief investment officer of Thomvest Asset Management Inc., said: "We see 2017 as a transformational year for ProMetic. The commercialization of the company's first plasma-derived therapeutic will validate its proprietary PPPS platform and should focus the market's attention on the therapeutic pipeline it enables. ProMetic is demonstrating how good strategy, innovation and execution can be combined to bring cost-effective novel therapies to patients while creating value for all stakeholders. We are proud to support Mr. Laurin and the rest of the ProMetic team in their efforts."

The loan shall be secured by ProMetic's assets, excluding its patent portfolio. The redemption value of the loan implies a compounded annual interest rate of 8.5 per cent. No interest or principal shall be required to be repaid prior to July 31, 2022. As part of this transaction, ProMetic shall grant Structured Alpha LP a warrant to purchase 10,600,407 common shares at an exercise price of $3.70 per common share with a term expiring in October, 2023. The proceeds received by ProMetic from the aggregate exercise of all of the warrants would be sufficient to repay the loan in its entirety. No material additional security or covenants have been granted to Structured Alpha LP, over those already in place by the current original issue discount notes.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences is a biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic is active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small molecule products are under development for orphan drug indications.

We seek Safe Harbor.